AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00207285 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sleep Hygiene Education
Description: Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
Study NCT00207285 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Screening and Treatment of Sleep Disorders
Description: All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
Study NCT03686397 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SVT-15652
Description: 1 vial twice daily
Study NCT03686397 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 vial twice daily
Study NCT01531283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unacylated ghrelin
Description: IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
Study NCT01531283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acyl ghrelin
Description: IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
Study NCT01531283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combined acyl and desacyl ghrelin
Description: IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
Study NCT01531283 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: IV, saline, one time, for the duration of the study visit(approximately 5 hours)
Study NCT02643004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A
Description: contact lens
Study NCT02643004 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stenfilcon A
Description: contact lens
Study NCT04771533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a sitting position
Description: The subject sat on the therapeutic table (without back support), feet resting on the floor. The upper limb was to be examined in adduction of the humeral joint, with the elbow bent in the intermediate position between pronation and supination of the forearm, with free wrist and the hand. After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study NCT04771533 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hand motor coordination in a supine position
Description: In the supine position, the upper limb was stabilized at the subject's body (adduction in the humeral joint, elbow flexion in the intermediate position, wrist and the hand free). After putting the glove on, the range of passive movement in the radial-carpal joint (flexion and extension) and fingers (global flexion and extension) was measured. Then the subject made active movement in the same order. Finally, the subject was asked to make moves as quickly and in as full a range as possible. Finally, the measurement of grip strength with a dynamometer was performed.
Study NCT00616109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
Study NCT00731874 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Dosed to achieve target trough concentrations.
Study NCT03595540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prolon
Description: Prolon by L-Nutra is a medically-designed dietary kit providing the food to eat for five days. Day 1 of Prolon provides \~4600 kJ (11% protein, 46% fat, and 43% carbohydrate), whereas days 2-to-5 provide \~3000 kJ (9% protein, 44% fat, and 47% carbohydrate) per day.
Study NCT04415476 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Assigned Interventions
Description: This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
Study NCT04415476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Assigned Interventions
Description: This is a prospective single-center, open-label, randomized, controlled pilot study in the treatment of chronic rejection (CR), defined as grade 1 and 2 BOS, in adult recipients of a pulmonary allograft (single or double lungs). Patients meeting entry criteria shall demonstrate a sustained decline in FEV1 having met stage 1 or 2 BOS. Patients randomized to the study arm, will be treated with Sirolimus (S) orally in place of MMF in addition to tacrolimus and prednisone compared to those patients randomized to defined ST alone (tacrolimus, MMF and prednisone). The trial duration will be approximately 2 years for each subject randomized. Treatment compliance and safety will be monitored by clinic visits at 4-6 week intervals for the 2 year subject duration and will include standard physical examinations and monitoring of routine clinical and laboratory parameters including cause of hospitalizations and rate of adverse events including death in each group. T
Study NCT00697567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant
Description: Intramuscular injection, 3 doses
Study NCT00697567 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant
Description: Intramuscular injection, 3 doses
Study NCT01482364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Integrated hemodynamic management (IHM) - HOTMAN System
Description: Therapeutic approach according to HOTMAN System measurement(ICG)results .
Study NCT01482364 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System
Description: Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
Study NCT02002975 — intervention group
Intervention type: DRUG
Intervention: Pioglitazone
Description: Pioglitazone tablets
Study NCT06268691 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Insecticide Coating INESFLY
Description: The IC is an aqueous solution containing polymeric microcapsules of insecticides and insect growth regulators (pyriproxyfen-PPF (0.063%) and alphacypermertrin-ACM (0.7%) in suspension, without interaction between them, developing by INESFLY Corporation, key achievement of the year 2017 TDR-WHO.
Study NCT01450033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Mentoring
Description: Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
Study NCT01450033 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: e-Communication with mentor
Description: Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
Study NCT03640039 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 3d strut plate.
Description: Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
Study NCT03640039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3d strut plate.
Description: Under general anathesia fracture will be exposed and fixed with 3d srut plate.Wound closed in standered fashion. patient will be released from operating room with out IMMF.
Study NCT03875261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabinoid treatment
Description: Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.
Study NCT05855265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: photon therapy face mask
Description: In this study the patients were randomly assigned into two equal groups after agreeing to participate through signing an informed consent.,Out of 70 identified Nasopharyngeal tumor receiving radiotherapy, only 60 subjects completed the full requirements of the study,Participant's age ranged from 30-60 yearsThe subjects in control group (CG) were treated with their medical treatment in addition to routine methods of nursing were given during radiotherapy including health education, skin self-care, and skin protective agent. 0.9% normal saline cotton balls will be used to gently clean the wound and remove necrotic tissue, and the wound was dried with sterile gauze.~The subjects in study group (SG) were received photon therapy during radiotherapy treatment. In addition to medical treatment and routine methods of nursing,
Study NCT03707535 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13
Description: 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
Study NCT03707535 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Remicade
Description: 3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid
Study NCT03002025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64304500
Description: Participants will receive JNJ-64304500 as SC injection.
Study NCT03002025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive matching placebo to JNJ-64304500 as SC injection.
Study NCT02633683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HORIZANT 600 mg
Description: HORIZANT 600 mg once daily
Study NCT03690635 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VISTA (vestibular incision subperiosteal tunnel acess)
Description: A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity.
Study NCT03690635 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VISTA (vestibular incision subperiosteal tunnel acess)
Description: A vertical incision will be made on the mucous membrane and the periosteum with a scalpel. The incision will be 8-10mm long, beginning from the mobile mucosa and reaching the apical end of the keratinized gingiva.~A small subperiosteal elevator will be inserted through the incision and is used to free the subperiosteal tunnel flap. The flap includes the tissues of the mobile and immobile mucosa in the area of the affected teeth and about 1 mm distally and medially from them.~Subperiosteal tunnel will be extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla.~Tunneling instruments will be used through the vertical incision to free the mucosa and the periosteum around the teeth affected by the gingival recession. This is continues at the base of the gingival papillae without affecting their integrity.
Study NCT02584556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: systemic chemotherapy
Description: Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
Study NCT02584556 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter Arterial Chemoembolization
Description: Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
Study NCT04228029 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Carboxytherapy
Description: Carbon dioxide (CO2) gas in injection form
Study NCT04228029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralesional Steroid Injection
Description: triamcinolone acetonide 8 mg/mL
Study NCT02949479 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Dissociation Investigation in Sex Offenders
Description: prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
Study NCT02817529 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulmonica
Description: The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
Study NCT02817529 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RC-Cornet
Description: RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
Study NCT02591498 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Study NCT02591498 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized cognitive training
Study NCT04330313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Traction
Description: Intermittent traction will be applied to the cervical region in a supine position with the neck at 25-30 ° flexion. The target weight is determined as 10% of the patient's weight. Traction pulling force applied to the target weight will be achieved gradually increasing from low. Traction therapy will be applied intermittent traction for 15 minutes in each session as 60 seconds retention and 60 seconds rest. The therapy will be held for 18 sessions, 3 days / week.
Study NCT04330313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Laser therapy will be applied to the participants with a GaAs laser with 904 nm wavelength, 6 points transforaminally, 120 seconds to each point, at 2 J / cm² density, total dose of 12 J laser therapy by keeping the probe in constant contact with the skin.
Study NCT04330313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hot pack
Description: The hot pack, which is the superficial heat agent, will be held in the neck area of the participants for 20 minutes in each session.The therapy will be held for 18 sessions, 3 days / week.
Study NCT04330313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stretching
Description: Stretching exercises will be repeated 3 times a day in total, 2 times a day self-stretching at home and 1 time under the supervision of a physiotherapist. Exercises for upper trapezius muscle, sternokleudomasteudeus (SCM) muscle and the scalene muscle to be applied in a 3 repeat by waiting 30 seconds, stretching under tension.The therapy will be held for 18 sessions, 3 days / week.
Study NCT04059536 — intervention group
Intervention type: DEVICE
Intervention: Roxwood Anchoring Catheters
Description: Anchoring catheters
Study NCT04059536 — intervention group
Intervention type: DRUG
Intervention: Acetylsalicylic Acid
Description: Oral Tablet
Study NCT04059536 — intervention group
Intervention type: DRUG
Intervention: Heparin
Description: Intravenous Injection
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Single food Cue Exposure Treatment
Description: Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single food Cue Exposure Treatment
Description: Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multiple food Cue Exposure Treatment
Description: Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multiple food Cue Exposure Treatment
Description: Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement - Enhanced Cue Exposure Treatment
Description: Subjects will take random additional tastes of the food during cue exposure treatment.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial Reinforcement - Enhanced Cue Exposure Treatment
Description: Subjects will take random additional tastes of the food during cue exposure treatment.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial Reinforcement -Consistent Cue Exposure Treatment
Description: Subjects will consistently take the same tastes of the food during cue exposure treatment.
Study NCT01708785 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Partial Reinforcement -Consistent Cue Exposure Treatment
Description: Subjects will consistently take the same tastes of the food during cue exposure treatment.
Study NCT00260962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine
Description: After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
Study NCT00260962 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Day Hospital
Description: Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
Study NCT00260962 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Day Hospital
Description: Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
Study NCT03207035 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Axillary brachial plexus block
Description: Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
Study NCT03207035 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Axillary brachial plexus block
Description: Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
Study NCT01756170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT01756170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT01756170 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Study NCT01756170 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Study NCT00015834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given PO
Study NCT00015834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT01613846 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib+Pazopanib
Description: Sorafenib (first-line) followed by Pazopanib (second-line)